Combining simplex and multiplexing capabilities with PentaBase’s unique DNA technologies and open platform designs, SensiScreen® assays deliver profound sensitivity and flexibility in the analysis of somatic mutations, to aid in the selection of proper cancer treatment based on the patient’s mutational status
Common cancers including colorectal cancer, lung cancer and malignant melanoma are characterized by the accumulation of somatic mutations, some of which are known to affect a patient’s response to cancer treatments. Our qPCR-based assays provide fast and reliable somatic mutation detection to support rapid initiation of the optimal cancer treatment.
The assay is available in 2 formats:
Analysis of liquid biopsies
Analysis of FFPE biopsies
Our liquid biopsy screening assays provide highly effective analysis of somatic mutations done on top-of-the-line real-time PCR equipment. The high sensitivity of the assays allows the detection of down to one copy of genomic human DNA in liquid biopsies. In addition to its use as an aid in treatment selection, the liquid biopsy assays are highly suitable for monitoring a patient’s response progression and resistance to cancer therapies using liquid biopsies. Thereby, it allows for a more personalized treatment planning and adjustment. Assays can be provided as either Ready-to-use (RTU) or Dispense-ready (DR) versions to offer optimal convenience for the operating laboratories.\
Result in less than three hours
Limit of detection down to one cop
Simplex or multiplex configurations.
High sensitivity and cost-effective
Covered Mutations
BRAF V600: The Assay is intended for identification of the mutations V600D/E/K/R in the BRAF gene.
KRAS: The assays identify 23 mutations in KRAS exon 2, 3 and 4. They are made for identification of mutations in codons 12, 13, 59, 61, 117 and 146 of the KRAS gene.
KIT: This assay identifies the aspartic acid (D) to valine mutation in codon 816 of the KIT gene (D816V). NRAS: The assays identify 24 mutations in NRAS exon 2, 3 and 4. The assays are intended for identification of mutations in codons 12, 13, 59, 61, 117 and 146 of the NRAS gene.
PIK3CA: The assays identify three mutations in codon 1047. The assays are intended for identification of the mutations H1047L/R/Y in the PIK3CA gene.
V-raf: / EGFR:
Sample type: FFPE from solid biopsies and Liquid biopsies ( from Blood plasma)
SensiScreen® FFPE benefits:
Result in less than three hours Limit of detection down to point 0.25 per cent of mutated DNA High sensitivity and cost-effective Simplex or multiplex configurations